tradingview.comSEP 221 min read$ADPT

BTIG maintains Buy rating on Adaptive Biotechnologies, $34 price target

BTIG kept a Buy rating on Adaptive Biotechnologies with a $34 price target, suggesting a 22% upside from the Sep 21 close. The firm cited strong revenue growth, including a 22% YoY increase to $72M in Q2'26, and NCCN guideline updates supporting clonoSEQ for multiple myeloma assessments.

Original reporting

tradingview.com

Published Sep 22, 2026, 10:09 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 22, 2026, 11:27 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

BTIG maintains Buy rating on Adaptive Biotechnologies, $34 price target — source image — Source · tradingview.com

Decision brief

The 30-second read

$ADPTBullishMed

Why it matters

The rating and target upgrade could attract new buying interest.

Market read

Analyst upgrade provides a fresh catalyst for ADPT, potentially driving short-term price movement.

What to watch

Potential reimbursement challenges and upcoming competition.

Relevance 7/10Novelty 6/10Timing: today

Background

BTIG's note follows Adaptive Biotechnologies' recent revenue growth and NCCN guideline inclusion.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ADPTBullishMedium confidence

Context

BTIG maintained a Buy rating and raised the price target to $34, implying a 22% upside.

Expected impact

Potential upside of ~20% if market reacts to the higher target.

Evidence & confidence

Rating maintenance with a higher target provides a fresh catalyst for traders.

Market effects

Sector

May boost sentiment in the biotech diagnostics sector.

Regional

Limited to US biotech equities.

Global

Low global impact.

Counterpoint

What could challenge this read

The price target may be overly optimistic given competitive pressures.

Key entities

Company
Adaptive Biotechnologies
Biotech firm developing MRD diagnostic tests.
Analyst
BTIG
Brokerage firm providing the rating.

Read at source ← All news

SEP 21

$ADPTHigh

BTIG raises Adeptus Biotechnologies price target to $34 on guidelines

BTIG raised its price target for Adeptus Biotechnologies (ADPT) to $34 from $25, citing updated cancer guidelines that feature its clonoSEQ assay. The stock has gained 109% over the past year. Adaptive Biotechnologies reported Q2 revenue of $71.6M, up 22% YoY, but missed earnings estimates. Guggenheim and BTIG also raised their price targets for Adaptive Biotechnologies.

investing.com2 min

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

JUL 29

$ADPTMed

Adaptive Biotechnologies Corp (ADPT): Results of Operations and Financial Condition

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene

SEC EDGAR 8-K6 min

JUN 5

$ADPTMedAI 9/10

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotechnologies (NASDAQ:ADPT) reported Q1 2026 revenue of $70.9 million, up 35% year over year, driven by its MRD business, which generated 95% of revenue and rose 53%. clonoSEQ test volume increased 41% to 32,595. Net loss narrowed to $20.0 million; non-GAAP Adjusted EBITDA loss was $2.5 million. The company raised full-year 2026 MRD revenue guidance to $260–$270 million.

finance.yahoo.com4 min

SEP 22

$GRABMed

Grab stock jumps after CEO purchases $29.9M in shares

Grab Holdings Ltd (NASDAQ:GRAB) shares rose 6.2% after CEO Anthony Tan purchased 10,350,000 Class A shares for $29.9M, averaging $2.89 per share. The transaction, disclosed in a SEC filing, is seen as a vote of confidence in the company's future.

investing.com1 min